Covid-19 vaccine update: Bharat Biotech begins phase 3 trials, Moderna says its candidate nearly 95% effective

Meanwhile, Johnson and Johnson has launched a second phase 3 trial, besides its existing one. Also, India is reportedly in talks with several firms over their respective coronavirus vaccine candidates with regards to the progress of trials, vaccine efficacy, safety etc.
FILE PHOTO: A man rides his motorcycle past a parked bus of Bharat Biotech outside its office in Hyderabad (REUTERS/Stringer/File Photo)
FILE PHOTO: A man rides his motorcycle past a parked bus of Bharat Biotech outside its office in Hyderabad (REUTERS/Stringer/File Photo)
Updated on Nov 17, 2020 08:57 AM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Karan Manral

A worldwide search for a vaccine to treat the coronavirus disease (Covid-19) continues, even as the number of cases globally, due to the pandemic, currently stands at more than 55 million including more than 1.3 million people who have succumbed to the virus, as per a tally maintained by worldometers.

Click here for full Covid-19 coverage

In the latest updates on a coronavirus vaccine, India’s Hyderabad-based Bharat Biotech International Limited has started phase 3 trials of its vaccine candidate. America’s Moderna, meanwhile, claimed its vaccine candidate has been found to be 94.5% effective.

Here are the latest updates on the coronavirus vaccine development front:

(1.) Bharat Biotech on Monday started phase 3 clinical trials of its vaccine candidate, COVAXIN. Phase 3 trials will involve 26,000 volunteers and will be conducted in partnership with the Indian Council of Medical Research (ICMR). This is the largest clinical trial for a Covid-19 vaccine candidate in India as well as the country’s first phase 3 efficacy study of a vaccine candidate. Bharat Biotech is developing COVAXIN in collaboration with ICMR and National Institute of Virology (NIV), Pune.

Also Read | Covid-19: Bharat Biotech begins Phase 3 trials of Covaxin in India

(2.) Also on Monday, US biotech firm Moderna released early results from a clinical trial of its Covid-19 vaccine candidate, mRNA-1273. The vaccine candidate, Moderna said, was found to be 94.5% effective. However, in what could be a potential hurdle for India, mRNA candidates need extremely cold environment for storage and transport. Last week, after Pfizer announced its candidate was 90% effective, All India Institute of Medical Sciences (AIIMS) director, Dr Randeep Guleria had said, “Pfizer vaccine has to be kept at minus 70 degrees Celsius which is a challenge for developing countries like India.”

Also Read | Covid-19 vaccine 90% effective in Phase 3 trial, says US pharma giant Pfizer

(3.) Johnson and Johnson, another US biotech firm working on a potential Covid-19 vaccine, has launched a second global phase 3 vaccine trial, besides an existing one. This latest trial has been named ENSEMBLE 2 and differs from other trials, including J&J’s own existing trial, in that it will explore a 2-dose regimen; most other trials are based on a 1-dose regimen. ENSEMBLE 2 will enrol up to 30,000 participants in the US, the UK, France, Germany, South Africa, Spain, Belgium, Colombia and the Philippines.

(4.) India is reportedly in talks with various firms over their potential vaccine candidates. Government officials are said to be in talks with firms like Moderna, Pfizer, Serum Institute of India (SII), Bharat Biotech and Zydus Cadila over the progress of the trials of their respective vaccine candidates, vaccine efficacy, safety, regulatory approvals etc.

(With agency inputs)

SHARE THIS ARTICLE ON
Close Story
SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Monday, May 23, 2022